Gen reports on advances in dna vaccine delivery and production – China Parking Control Terminal

Scientists involved in DNA vaccine research are currently focusedon two major issues: the creation of effective delivery systems andthe development of more efficient biomanufacturing strategies,reports Genetic Engineering & Biotechnology News (GEN). Topinvestigators in the field recently discussed these and othertopics at a conference in San Diego entitled “DNA Vaccines:Building on Clinical Progress and Exploring New Targets,” which wassponsored by the International Society of DNA Vaccines andorganized by BioConferences International, a Mary Ann Liebertcompany, according to the September 1 issue of GEN . David Weiner, Ph.D., University of Pennsylvania professor andconference chair, noted that despite some early setbacks, DNAvaccine technology has advanced dramatically over the past fewyears and that therapies currently under evaluation aredemonstrating the superb potential of plasmid-based vaccines. Heemphasized that a range of novel vaccine methodologies haveemerged, including new strategies for getting the plasmids intocells, increasing protein production once they are inside, andmodifications of the vaccine proteins that increase theirrecognition and response by the immune system. Some of the more promising delivery approaches include transdermal,needle-free patches, devices that transport the plasmids into theskin via air pressure, and electroporation, in which electricalpulses are used to temporarily open the cell membrane, allowing theplasmids easier access to the interior of cells. Flap Barrier

On the manufacturing front, Philippe Ledent, Ph.D., processtransfer and development manager at Eurogentec Biologics, explainedthat his company has faced major challenges scaling up the outputof both protein and nucleic acid products. For plasmid productionEurogentec turned to fed-batch protocols for better growth controlof the cultures, he said, adding that in a two-step process thatwas based on biomass expansion followed by plasmid DNA production,it was possible to increase fermentation yields 10-fold. Tony Hitchcock, head of manufacturing technologies atRecipharmCobra Biologics, provided another approach to plasmidpurification. The company’s product line includes bacteria, animalcells, viruses, novel proteins, and antibodies. The overall processthat Hitchcock sought to optimize was quite similar to thatfollowed by Eurogentec: high density fermentation, followed byalkaline cell lysis, chromatographic purification, and finalformulation. China Parking Control Terminal

Also covered in the GEN article are DNA vaccine productiontechniques used by Althea Technologies and VGXI. Additional References Citations. Folding Barrier Gate Manufacturer


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s